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Abstract
Background—Little is known about health providers’ attitudes toward visual inspection with 
acetic acid (VIA) and cryotherapy in the prevention of cervical cancer, as most research in Latin 
America and the Caribbean (LAC) has examined attitudes of the general population. This study 
describes attitudes of Bolivian health professionals toward new technologies for cervical cancer 
prevention, focusing on VIA and cryotherapy.
Methods—Between February 2011 and March 2012, we surveyed 7 nurses and 35 physicians 
who participated in 5-day workshops on VIA and cryotherapy conducted in Bolivia. Multiple 
choice and open-ended questions were used to assess participants’ acceptability of these 
procedures and the feasibility of their implementation in the context of perceived barriers for the 
early detection of cervical cancer in this country.
Results—Most believed that cultural factors represent the main barrier for the early detection of 
cervical cancer (70%), although all stated that VIA and cryotherapy would be accepted by women, 
citing the advantages of VIA over cytology for this belief. Most also believed their colleagues 
would accept VIA and cryotherapy (71%) and that VIA should replace Pap testing (61%), 
reiterating the advantages of VIA for these beliefs. Those who believed the contrary expressed a 
general resistance to change associated with an already existing cytology program and national 
norms prioritizing Pap testing.
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Conclusions—Most participants had favorable attitudes toward VIA and cryotherapy; however, 
a sizable minority cited challenges to their adoption by colleagues and believed VIA should not 
replace cytology. This report can inform the development of strategies to expand the use of 
alternative cervical cancer screening methods in LAC and Bolivia.
Introduction
Of an estimated 275,000 deaths worldwide from cervical cancer, approximately 88% occur 
in developing countries.1 In Latin America and the Caribbean (LAC), cervical cancer is the 
second leading cause of cancer-related death among women, with Jamaica, Guyana, 
Nicaragua, Honduras, El Salvador, and Bolivia having the highest incidence of and mortality 
rates from this disease.2 Infection with the human papillomavirus (HPV) high-risk types has 
been identified as a prerequisite for the development of cervical cancer. Although most 
infections with HPV resolve spontaneously, persistent infections may lead to precancerous 
lesions of the cervix and, ultimately, to cervical cancer if left untreated.3
In the United States and other developed countries, the implementation of cytology-based 
screening programs for cervical cancer has resulted in a significant decrease in deaths from 
this disease, whereas in most LAC countries, cervical cancer rates have increased or remain 
unchanged.4 Effective cytology-based programs require multiple clinic visits related to 
screening, diagnosis, and treatment, as well as a substantial infrastructure to process and 
interpret cytology slides, perform colposcopy, process and interpret biopsy specimens, and 
provide treatment services. These services are poorly coordinated, limited, or simply 
nonexistent in LAC, which has resulted in ineffective cytology programs in most countries.5
Since 1999, the Pan American Health Organization (PAHO) in partnership with the Alliance 
for Cervical Cancer Prevention (ACCP) has been conducting research in low resource 
settings to assess the safety and effectiveness of screening based on visual inspection with 
acetic acid (VIA), HPV DNA testing, and treatment with cryotherapy.5 Demonstration 
projects and randomized controlled screening trials have found that the effectiveness and 
efficiency of a single visit screen-and-treat strategy using VIA testing followed by treatment 
with cryotherapy are high.6–8 VIA has sensitivity equal to or greater than the Pap test in 
detecting high-grade dysplasia, requires simple equipment, and provides immediate results. 
Cryotherapy is also more appropriate for low resource settings, as it does not rely on 
electricity and is inexpensive.9 Lastly, both procedures can be performed by trained nurses 
or other non-physicians who are more available in rural areas.10 Although HPV DNA testing 
as a primary screening method has been found to be more effective than VIA in reducing 
cancer and cervical cancer mortality,11 the currently available HPV test is expensive and 
requires substantial laboratory infrastructure. Thus, the CareHPV test, which is a simpler 
and more affordable type of HPV test, is currently being developed and represents a 
promising tool for the secondary prevention of cervical cancer in low resource settings, as it 
allows for self-sampling and results are available within 2 hours.12,13
Based on the potential of these new, alternative approaches, PAHO has developed a Regional 
Strategy for Comprehensive Cervical Cancer Prevention and Control for 2008 through 
2015.14 This strategy aims to strengthen health services along the continuum of care, from 
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primary and secondary prevention to treatment and palliative care. A key priority has been 
the introduction of alternative, more practical methods for delivery of screening services and 
treatment of precancerous lesions. As a result, interventions for capacity building in VIA 
and cryotherapy are taking place in several LAC countries.
As part of the collaboration in cancer between the U.S. Centers for Disease Control and 
Prevention (CDC) and PAHO,15 staff from these organizations have partnered with the 
Bolivian Ministry of Health (MOH) and the Peruvian National Cancer Institute (INEN) to 
increase capacity building for VIA and cryotherapy among Bolivian providers. To date, two 
courses have been taught in La Paz and one in Perú to provide Bolivian physicians and 
nurses with the basic clinical skills to perform these procedures. These are the first of a 
series of workshops to be conducted in Bolivia as part of the CDC-PAHO collaboration.
Bolivia: Background
Of 10.4 million Bolivian inhabitants, an estimated 62% are of indigenous descent.16 
Approximately 19.3% of Bolivian females speak only an indigenous dialect compared to 
6.9% of males.17 The country is divided into nine regions (departamentos), and 
approximately 66.3% of the population live in urban areas and 60.1% are below the poverty 
line.18 Figure 1 shows the geographic distribution of Bolivia’s nine regions.
Cervical cancer prevention and control in Bolivia
Bolivia has age-standardized incidence and mortality rates for cervical cancer of 
36.4/100,000 and 16.7/100,000, respectively.2 Although this country does not have an 
organized program dedicated to cervical cancer screening, a national cervical cancer 
prevention and control plan has been in place since 1988. A unit for the detection and 
control of women’s cancer (Componente de Detección y Control del Cáncer de la Mujer) 
was established in 1989 and currently operates under the MOH unit for sexual and 
reproductive health. Bolivia has a decentralized model of healthcare provision in which local 
health departments, or Servicios Departamentales de Salud (SEDES), are in charge of the 
allocation of funds and resources provided by the MOH.19 Since 2006, the Pap test is 
offered free of charge to all women through the Maternal and Child National Health 
Insurance Program, or Seguro Universal Materno Infantil (SUMI); however, the screening 
coverage of the target population is only 14%.20 Screening, diagnostic services, and 
treatment of precancerous lesions and simple hysterectomies as treatment for carcinoma in 
situ are offered at no cost through the SUMI. Services for treatment of cervical cancer are 
available for a fee through the public healthcare system.
In 2009, the Bolivian MOH unit for the detection and control of women’s cancer developed 
a comprehensive plan for cervical cancer prevention and control for 2009–2015.21 This plan 
prioritizes cytology as a primary screening method, recommends screening every 3 years 
after two consecutive negative Pap tests, and incorporates the use of VIA and cryotherapy on 
a smaller scale.22 At this time, the HPV vaccine is being administered by a nongovernmental 
organization to a large group of the target population in a demonstration project that has 
achieved high coverage and acceptability, with minimal adverse effects.23
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Most research on VIA and cryotherapy in LAC has focused on their feasibility, 
effectiveness, safety, and acceptability by the general population. Thus, little is known about 
providers’ attitudes toward these alternative technologies. Because acceptability of these 
procedures by health providers is key to their successful implementation in Bolivia, this 
initial study reports the key findings on (1) provider knowledge and attitudes on VIA and 
cryotherapy, (2) physicians’ attitudes toward the role of nurses as providers of VIA and 
cryotherapy services, and (3) perceived barriers to cervical cancer prevention efforts. The 




Between February 2011 and March 2012, we surveyed a group of 42 Bolivian health 
professionals who participated in one of two basic 5-day workshops on VIA and cryotherapy 
conducted at the Women’s Hospital in La Paz. The group of participants attending the first 
offering included 7 nurses and 14 physicians from five regions: La Paz, Potosí, Sucre, Oruro, 
and Pando. At least 1 nurse, 1 general practitioner, and 1 obstetrician/gynecologist were 
selected from each of these regions. Most participants of the first offering worked for local 
health departments. A separate group of 21 physicians who worked for local health 
departments attended the second offering of the workshop.
Two questionnaires were developed to assess attitudes toward alternative methods for 
cervical cancer screening and treatment of precancerous lesions. Some questions were 
selected, adapted, and translated from existing survey tools,24 but most were drafted based 
on issues specific to Bolivia and the LAC region as a whole. All survey items were drafted 
and translated by a native Spanish speaker and revised for content, clarity, and relevance by 
both native English and Spanish speakers.
Procedure
As we were interested in assessing attitudes toward VIA and cryotherapy after participants 
had learned about these technologies through course materials, two questionnaires were 
administered at two different times. A questionnaire consisting of multiple choice questions 
was administered at the beginning of the first workshop day to assess current cervical cancer 
screening practices, perceived barriers to the early detection of cervical cancer, and attitudes 
of physicians toward the role of nurses in the provision of VIA and cryotherapy services. A 
second questionnaire consisting of multiple choice and open-ended questions was 
administered on the last workshop day to assess acceptability of VIA and cryotherapy, 
perceived barriers for the implementation of these procedures using a single-visit screen-
and-treat approach, and acceptability and familiarity with HPV testing and HPV vaccination. 
Participants were given 30 minutes to complete each questionnaire. Both questionnaires 
were part of a larger survey administered by local PAHO staff for program evaluation 
purposes, and CDC received de-identified data for analysis. All participants completed both 
questionnaires. Codes to organize and categorize responses to open-ended questions were 
Stormo et al. Page 4













developed through an inductive approach. The data were analyzed using SPSS 14 statistical 
software.
Results
Participants included a total of 35 physicians and 7 nurses (Table 1). Most physicians were 
obstetrician/gynecologists (71%), were male (51%), and had practiced medicine for an 
average of 14 years. As shown in Table 2, 58% of participants believed that VIA is very 
effective, and almost half stated this belief for HPV testing. Knowledge on the self-collected 
HPV test seemed very limited, with only 7 participants stating they were familiar with the 
advantages of this test.
Attitudes toward VIA and cryotherapy
Except for 1 participant who did not provide an answer, all reported that VIA would be 
accepted by their patients (Table 2). When asked to provide reasons for this belief, the vast 
majority cited the advantages of VIA over cytology and issues related to the ineffectiveness 
of the current system to implement cytology-based screening:
“[VIA] is fast and simple.”
“Because our patients would not have to come back 2 weeks later or a month later 
to get the results, as it is usually the case [with the Pap test].”
“VIA is cheap and more accessible because it can be performed by nonphysicians.”
“Women no longer trust the Pap test because it takes a long time to get the results 
back. VIA is [also] much cheaper.”
Seventy-one percent reported that their colleagues would accept VIA as a screening method 
(Table 2), with most reporting the advantages of this procedure (e.g., low cost and immediate 
results) over cytology for this belief. The nearly 30% who stated the contrary cited general 
distrust and resistance toward the use of VIA for this belief. The perceived resistance from 
colleagues to accepting VIA as a screening method is reflected in the following answers:
“Because [physicians] are not up-to-date and have this idea that VIA does not 
provide good results.”
“[Due to] lack of credibility in the sensitivity [of VIA] and lack of training.” “It’s 
been many years [since physicians started] working with the Pap test. They also 
have little information about VIA and its benefits.”
“There is a lot of controversy and distrust regarding [VIA].”
Approximately 61% believed that VIA should replace Pap testing, citing the advantages of 
VIA over cytology (Table 2). Most participants who believed that VIA should not replace 
the Pap test stated that in their specific health facility Pap testing works well:
“The cytology-based system is more optimal, and adequate follow-up is provided.”
“In my health facility, Pap results are received within 24 hours.”
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“Because [in my health facility] we have a pathologist and we [provide] follow-
up.”
Many were also confused about the role of VIA and believed that the Pap test and VIA serve 
different purposes and could be performed together instead of one replacing the other:
“I can perform both procedures. The Pap can diagnose other pathologies. [VIA and 
Pap testing] can synergize with each other.”
“[VIA and Pap testing] complement each other, they are complementary 
techniques.”
A total of 42% reported seeing challenges to the implementation of a single-visit screen-and-
treat approach using VIA and cryotherapy in their specific health facility (Table 2), citing 
lack of equipment (88%) and capacity (50%) as main barriers to implementation of this 
approach. When asked about the main barriers women would face at their specific health 
facility to receive follow-up after cryotherapy treatment, most cited long distances from 
women’s homes to the health facility:
“Many patients come from rural areas, and due to lack of medical staff many 
appointments are usually postponed.”
“[Women] have to wake up early [to go to the hospital] and make an appointment. 
These are women coming from areas that are very far.”
Many others explained that the main barriers to conduct appropriate follow-up are long waits 
on the day of the scheduled appointment and lack of capacity and materials:
“At 7 am [women] arrive at their appointment [at the health facility] and around 
10–11 am they receive care.”
“A large number of patients and lack of medical personnel.”
Lastly, some participants emphasized characteristics of the population as barriers to conduct 
follow-up:
“If we were to perform cryotherapy [the main barriers] would be […] constant 
changes in patients’ addresses.”
“Having a migrant, dispersed population without telephone numbers.”
Nearly 75% of participants believed that these alternative methods would have an impact on 
local healthcare systems (Table 2), with most of those who reported a positive impact 
reiterating the advantages of VIA over cytology. Many also stated that the adoption of new 
methods, such as VIA, could have a positive impact on other health services. As one 
participant stated:
“Making [women] aware of a new test [for cervical cancer screening] will attract 
more women, increasing demand and coverage for other services.”
Others stated that promoting VIA might decrease the number of other procedures commonly 
performed, which, in turn, could negatively affect pathologists and those working in 
cytology laboratories:
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“It would reduce the number of Pap tests, which is not beneficial for pathologists.”
“There will be less work in cytology labs.”
“It would decrease [the number of] hysterectomies performed and the number of 
Pap tests [performed].”
Perceived barriers to cervical cancer prevention
Fifty-two percent reported that the level of awareness about cervical cancer among the 
general population is low (Table 2). Over 75% reported that cultural factors represent the 
main general barrier to early detection of cervical cancer. When asked for specific barriers to 
cancer prevention efforts, most cited taboos related to Pap testing (71%) and lack of 
infrastructure and educational campaigns targeting women (52%).
Nurses’ role in provision of VIA and cryotherapy services
Both physicians and nurses in this study were asked about their attitudes toward the more 
active role that nonphysicians might play in the provision of VIA and cryotherapy services. 
Whereas the vast majority of physicians reported feeling comfortable with nurses 
performing VIA (74%), a little over half (56%) reported feeling comfortable with nurses 
performing cryotherapy (Table 3).
Discussion
VIA and cryotherapy can help overcome the major challenges that have kept screening 
access and coverage low in countries like Bolivia. However, knowledge about VIA and 
cryotherapy is still very limited in LAC, and continuing efforts to promote their introduction 
are crucial for the eventual institutionalization of these technologies in the region.25 Overall, 
our findings suggest that most participants selected for training in VIA and cryotherapy have 
favorable attitudes toward the introduction of these technologies in Bolivia. Most also 
believed that VIA and cryotherapy would be accepted by health professionals and women, 
citing the advantages of these procedures as a reason for this belief.
Most participants believed that a single-visit screen-and-treat approach using VIA and 
cryotherapy is feasible in Bolivia; however, VIA represents a more viable option than 
cytology even if cryotherapy is not immediately performed, as VIA provides immediate 
results, reducing the number of visits needed to receive treatment.26 In fact, a recent PAHO 
demonstration project conducted in Peru revealed that women screened with VIA were more 
likely to receive treatment for precancerous lesions than those screened using cytology.27
Adequate follow-up of women with positive Pap test results has been the main challenge to 
the successful implementation of cytology-based programs in LAC, including Bolivia, where 
< 20% of eligible women receive treatment for precancerous lesions.28 As most cytology-
based services are available in urban areas, women need to make costly trips to health 
facilities to get screened and receive diagnostic and treatment services if needed. At facilities 
offering these services, women experience long delays to receive care or Pap test results.29 
Although VIA can be made easily available in rural areas, participants in our training 
workshops believed that excessive delays to receive care and long distances between 
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women’s homes and health facilities represent impediments to provide follow-up to women 
who have received cryotherapy treatment. These findings suggest that limitations inherent to 
issues that are country specific and not to cytology-based programs per se are perceived as 
barriers to implementing widespread screening programs in Bolivia. It will be important as 
alternative technologies are incorporated into the healthcare system that efforts are made by 
the MOH to decentralize care and organize services more efficiently.
One of the major advantage of VIA is that it can be performed by nonphysicians, which may 
aid in efforts to decentralize care and reach high-risk populations living in remote areas. The 
Bolivian MOH selected 7 nurses to participate in CDC-supported workshops and plans on 
further increasing capacity among nurses. Although all nurses who participated in our 
workshops reported feeling comfortable in their new role as VIA and cryotherapy providers, 
only a little over half of physicians reported feeling comfortable with nurses performing 
cryotherapy. These findings are not surprising, as physicians have historically been in charge 
of making therapeutic decisions about eligibility of women for treatment of precancerous 
lesions. The experiences of the ACCP in training both nurses and physicians on VIA and 
cryotherapy have shown that nurses experience difficulty in making therapeutic decisions, 
which makes concerns from some of the physicians in our workshops consistent with the 
experiences of ACCP trainers.29 Attitudes toward nurses performing cryotherapy, however, 
should be further explored through a qualitative approach to understand underlying issues 
that may be causing concerns among some physicians.
In the present study, cultural factors were perceived by most health professionals as the main 
general barrier to cervical cancer prevention efforts, perhaps underestimating the limitations 
of the healthcare system in preventing women from receiving proper care. Our findings, 
however, are consistent with those of a previous population-based survey in the 
departamento of Sucre, which found that 90% of surveyed males disapproved of their female 
partners having a Pap test. The same study also found that the main factors preventing 
women from getting a Pap test were shame and fear.30 A recent qualitative assessment found 
that in many parts of the country, men are the ones deciding whether or not women should 
get screened or receive treatment and that many women do not seek care because of the 
stigma attached to the Pap test.28 This is consistent with our findings showing that most 
physicians believe that taboos about Pap testing represent the major specific barrier for early 
detection of cervical cancer in Bolivia.
Lack of public health education campaigns was another specific barrier reported by 
participants in our study, which parallels the findings of a recent qualitative assessment 
showing that educational materials on cervical cancer were limited or inexistent in most 
health facilities, that providers tend to prioritize education on reproductive health and other 
health issues before cervical cancer, and that most women did not know the purpose of the 
Pap test.28 Education efforts may prove an effective strategy to increase cervical cancer 
screening coverage, as 44% of women in Sucre who reported having been screened at least 
once in their lifetime cited receiving information on cervical cancer as the main reason for 
seeking care.30 Because men participate in the health decisions of women, it is important 
that health education and promotion strategies for the Bolivian public are tailored toward 
both men and women.
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Successful cervical cancer control and prevention are possible when screening, diagnostic, 
and treatment services are widely available.31 This can be achieved in Bolivia and other 
LAC countries by implementing such cost-effective methods as VIA and cryotherapy, which 
are also more appropriate to the region’s health infrastructure and resources. For VIA to be 
effective in increasing the screening coverage and demand for cryotherapy services, raising 
awareness about this disease by addressing sociocultural barriers among the population 
through health promotion efforts will be crucial. VIA represents a long-term strategy for 
Bolivia, as this procedure may also allow, in the long term, for adoption of HPV testing as a 
primary screening method, which will require a triage test to avoid a large number of 
referrals to colposcopy.12 This country recently participated in PAHO’s ProVac initiative to 
learn about cost-effectiveness strategies for introduction of HPV vaccination,32 but potential 
plans for adoption of HPV vaccines are simply one component of a comprehensive cervical 
cancer prevention plan for the country that will continue to include screening as a key 
strategy.
The present study is an initial assessment of health professionals’ attitudes toward alternative 
strategies for cervical cancer prevention in Bolivia, and the findings are not intended to 
represent the attitudes of health professionals in the country as a whole or in specific 
regions. In addition, our final sample was small, and we used two separate groups of 
participants to gather all data for this study. Because we used a self-report survey, social 
desirability bias may have also influenced our results. Despite these limitations, this 
assessment is the first to provide an overview of Bolivian health professionals’ attitudes 
toward VIA and cryotherapy and may be helpful as a starting point to inform the 
implementation of these technologies in Bolivia and the LAC region. Further, this 
information will be valuable for future initiatives conducted in LAC as part of CDC’s global 
strategy for cervical cancer prevention and control.33
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The nine regions of Bolivia. (Courtesy of Tom Richards.)
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Table 1
Distribution of Selected Demographic, Practice, and Professional Characteristics of Participants, Bolivia, 
2011–2012 (n= 42)
Item n (%)
Type of health professional
 Physician 35 (83.3)
 Nurse 7 (16.7)
Mean age (SD) 40.4 (8.0)
Physician gendera
 Female 17 (48.6)
 Male 18 (51.4)
Physician specialtya
 FP/GP 9 (25.7)
 OB/GYN 25 (71.4)
 Oncology 1 (2.9)
Physician mean years in practicea (SD) 14.0 (6.2)
Performed Pap test 37 (90.2)
Performed VIA prior to workshop 18 (46.2)
Performed cryotherapy prior to workshop 4 (14.3)
Perceived impact of national guidelines on clinical practicesb
 High 16 (40.0)




Percentages may not add to 100 due to missing values.
FP, family practice; GP, general practice; OB/GYN, obstetrics/gynecology; SD, standard deviation; VIA, visual inspection with acetic acid.
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Table 2
Knowledge, Attitudes, and Perceived Barriers Toward Alternative Technologies for Cervical Cancer 
Prevention, Bolivia, 2011–2012 (n = 42)
Item n (%)
Knowledge
 HPV infection and HPV vaccinea
  HPV increases risk for vaginal cancer 13 (31.0)
  Most women with HPV infection are asymptomatic 39 (95.1)
  HPV infection cause most cases of cervical cancer 37 (92.5)
  HPV vaccine protects against 2 types of HPV 39 (92.9)
  HPV vaccine may protect against vulvar cancer 18 (42.9)
  HPV vaccine may help prevent penile cancer 10 (24.4)
 Perceived effectiveness of screening testsb
  HPV 14 (46.7)
  VIA 23 (57.5)
  Cytology 12 (30.8)
 Familiar with the advantages of the self-collected HPV test 7 (17.1)
Attitudes on VIA and cryotherapy
 Acceptability
  Think patients would accept VIA and cryotherapyc 41 (100.0)
  Think their colleagues would accept VIA and cryotherapy 29 (70.7)
  Think VIA should replace the Pap test 25 (61.0)
  Think VIA and cryotherapy would have an impact on other health services 30 (75.0)
  Think performing VIA and cryotherapy in a single visit is not feasible in their specific health facility 17 (41.5)
 3 main challenges to implement a single visit screen-and-treat approachd
  Lack of equipment 14 (87.5)
  Lack of capacity 8 (50.0)
  Few health professionals in hospital/health center 4 (25.0)
Attitudes on HPV testing and HPV vaccine
 Would recommend the HPV vaccine to female patients 38 (92.7)
 Think incorporation of HPV testing is feasible within 5 years 8 (42.1)
Perceived barriers for early detection of cervical cancere
 General barriers
  Cultural 31 (75.6)
  Political 2 (5.0)
  Economic 3 (7.5)
  Organizational 4 (10.0)
 Specific barriersf
  The taboo about Pap testing among women 30 (71.4)
  Lack of educational campaigns and infrastructure 22 (52.4)
  Lack of dissemination of screening guidelines 17 (40.5)
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Item n (%)
  Lack of knowledge about cervical cancer 16 (38.1)
  Lack of priority given to women’s health 13 (31.0)
  Lack of infrastructure and organization of the Bolivian healthcare system 12 (28.6)
  The belief that cancer cannot be prevented 9 (21.4)
  The stigma related to cervical cancer for being a sexually transmitted illness 6 (14.3)
 Level of awareness among patients about getting screened for cervical cancer
  High 2 (4.8)
  Moderate 15 (35.7)
  Low 22 (52.4)
  None 3 (7.1)
All items were asked at pretest except for those related to attitudes on specific procedures.
a
No. of correct responses.
b




Participants were instructed to check all that apply. Only the most cited categories are presented.
e
Participants were given 4 barriers and asked to list them according to their level of importance in preventing early detection of cervical cancer.
f
Participants were asked to select 3 of the 8 barriers listed.
HPV, human papillomavirus; VIA, visual inspection with acetic acid.
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Table 3
Participants’ Responsibilities and Level of Comfort Providing Visual Inspection with Acetic Acid and 









 No. in charge of discussing Pap test results with patients 1 (16.7) 30 (85.7)
 No. in charge of follow-up of abnormal results 0 (0.0) 29 (82.9)
 No. in charge of recommending further testing for abnormal results 1 (14.3) 30 (85.7)
 No. in charge of reminding patients about an appointment 3 (42.9) 24 (70.6)
The new role of nurses regarding VIA
 Level of comfort performing VIA
  Comfortable 7 (100.0) 26 (74.3)
  Uncomfortable 0 (0.0) 9 (25.8)
 Level of comfort performing cryotherapy
  Comfortable 7 (100.0) 19 (55.9)
  Uncomfortable 0 (0.0) 15 (44.2)
 Level of comfort being in charge of follow-up of those treated with cryotherapy
  Comfortable 7 (100.0) 26 (76.4)
  Uncomfortable 0 (0.0) 8 (23.5)
 Discussing VIA results with patients
  Comfortable 7 (100.0) 27 (77.1)
  Uncomfortable 0 (0.0) 8 (22.9)
Participants were asked how comfortable they would feel with nurses performing procedures or being in charge of the activities listed. Nurses were 
instructed to indicate how comfortable they would feel undertaking the activities listed. A Likert-type scale was used to assess level of comfort for 
specified activities.
Percentages may not add to 100 due to missing values.
VIA, visual inspection with acetic acid.
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